Neurocrine Biosciences Stock EBITDA
| N1BI34 Stock | 35.67 0.00 0.00% |
Neurocrine Biosciences fundamentals help investors to digest information that contributes to Neurocrine Biosciences' financial success or failures. It also enables traders to predict the movement of Neurocrine Stock. The fundamental analysis module provides a way to measure Neurocrine Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Neurocrine Biosciences stock.
Neurocrine |
Neurocrine Biosciences Company EBITDA Analysis
Neurocrine Biosciences' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Neurocrine Biosciences EBITDA | 138.1 M |
Most of Neurocrine Biosciences' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Neurocrine Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
According to the company disclosure, Neurocrine Biosciences reported earnings before interest,tax, depreciation and amortization of 138.1 M. This is much higher than that of the sector and significantly higher than that of the Drug Manufacturers-Specialty & Generic industry. The ebitda for all Brazil stocks is notably lower than that of the firm.
Neurocrine EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Neurocrine Biosciences' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Neurocrine Biosciences could also be used in its relative valuation, which is a method of valuing Neurocrine Biosciences by comparing valuation metrics of similar companies.Neurocrine Biosciences is currently under evaluation in ebitda category among its peers.
Neurocrine Fundamentals
| Return On Equity | 0.1 | |||
| Return On Asset | 0.0701 | |||
| Profit Margin | 0.10 % | |||
| Operating Margin | 0.17 % | |||
| Current Valuation | 58.19 B | |||
| Shares Outstanding | 1.93 B | |||
| Price To Book | 7.33 X | |||
| Price To Sales | 44.39 X | |||
| Revenue | 1.13 B | |||
| Gross Profit | 1 B | |||
| EBITDA | 138.1 M | |||
| Net Income | 89.6 M | |||
| Total Debt | 335.1 M | |||
| Book Value Per Share | 0.88 X | |||
| Cash Flow From Operations | 256.5 M | |||
| Earnings Per Share | 0.41 X | |||
| Number Of Employees | 1.2 K | |||
| Beta | 0.48 | |||
| Market Capitalization | 51.64 B | |||
| Total Asset | 2.07 B | |||
| Z Score | 92.4 | |||
| Net Asset | 2.07 B |
About Neurocrine Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Neurocrine Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Neurocrine Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Neurocrine Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in Neurocrine Stock
When determining whether Neurocrine Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Neurocrine Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Neurocrine Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Neurocrine Biosciences Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurocrine Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade Neurocrine Stock refer to our How to Trade Neurocrine Stock guide.You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.